**New Section Added**

**Related Applications**

This application is a national stage filing under 35 U.S.C. § 371 of PCT application PCT/JP00/03639, filed June 5, 2000.

**Amended Claims**

3.(amended) The method according to claim 1 [or 2], wherein the RRF protein crystal is bipyramidal.

4.(amended) The method according to [any one of] claim[s] 1 [to 3], wherein the RRF protein crystal has a space group $P4_12_12_1$ or a space group $P4_32_12$.

5.(amended) The method according to [any one of] claim[s] 1 [to 4], wherein the RRF protein crystal has a size of $0.3 \times 0.3 \times 0.5$ mm.

6.(amended) The method according to [any one of] claim[s] 1 [to 5], wherein the RRF protein crystal has respective unit lattices of a size of a=b=47.3Å and c=297.6Å.

7.(amended) The method according to [any one of] claim[s] 1 [to 6], wherein the RRF protein crystal is characterized by a structure coordinate described in Table 7.

8.(amended) The method according to claim[s] 1 [to 7], wherein the RRF protein crystal is derived from Thermotoga maritima [Maritima].

9.(amended) The method according to [any one of] claim 1 [or 2], wherein the RRF protein crystal is orthorhombic.

10.(amended) The method according to [any one of] claim[s] 1, [2 and 9,] wherein the RRF protein crystal has a space group $P2_12_12$.

11.(amended) The method according to [any one of] claim[s] 1 [to 2 and 9 to 10], wherein the RRF protein crystal has a size of 30 × 50 × 250 µm.

12.(amended) The method according to [any one of] claim[s] 1 [to 2 and 9 to 11], wherein the RRF protein crystal is derived from strain X.

13.(amended) The method according to [any one of] claim[s] 1 [to 12], wherein the RRF protein crystal is crystallized by a drop-like vapour diffusion method.

14.(amended) The method according to [any one of] claim[s] 1 [to 13], wherein the RRF protein crystal is a heavy atom derivative and the crystal is any crystal of the RRF protein itself, an RRF protein mutant, an RRF protein homologue or an RRF protein co-complex.

15.(amended) The method according to [any one of] claim[s 1 to] 14, wherein the heavy atom derivative is formed by reaction of a compound selected from the group consisting of thyromethal, gold thiomalate, uranyl acetate and lead chloride.

16.(amended) The method according to [any one of] claim[s] 1, [2 and 9 to 12,] wherein the RRF protein crystal is a heavy atom derivative of platinum or mercury.

17.(amended) The method according to [any one of] claim[s] 1 [to 16], wherein the RRF protein is a monomer.

18.(amended) The method according to [any one of] claim[s] 1 [to 8, 13 to 15 and 17], wherein the RRF protein is characterized by amino acid displacement according to Table 5 or Table 6.

19.(amended) The method according to [any one of] claim[s] 1 [to 18], wherein a compound characterized by the chemical entity bound to the active site, accessory binding site or pocket is an inhibitor to the RRF protein.

20.(amended) The method according to [any one of] claim[s 1 to] 19, wherein the inhibitor is a competitive inhibitor, an uncompetitive inhibitor or a noncompetitive inhibitor to the RRF protein.

21.(amended) The method according to [any one of] claim[s] 1 [to 20], comprising determining orientation of a ligand at the active site or accessory binding site of the RRF protein.

22.(amended) The method according to [any one of] claim[s] 1 [to 8, 13 to 15 and 17 to 21], wherein the structure coordinate is a structure coordinate of the RRF protein according to Table 7.

47.(amended) The method according to [any one of] claim[s] 1 [to 22], wherein the pocket of the RRF protein is a pocket in the vicinity of C-terminal positioned on a folded part separating two domains of the RRF protein.

48.(amended) The method according to [any one of] claim[s] 1 [to 22], wherein the compound inhibits binding of the RRF protein to ribosome or inhibits behavior of the RRF protein on the ribosome.

49.(amended) The inhibitor to an RRF protein, obtained by the method according to [any one of] claim[s] 19 [to 23, 47 and 48].